

MINI PROGRAMME

**THE INTERNATIONAL
LIVER CONGRESS™**

APRIL 10 - 14, VIENNA, AUSTRIA

2019

Registration area – Foyer D

Membership fast-track, self-registration lanes, help desk, accommodation desk, congress material, congress app

Tuesday 09 April	16:00-19:00
Wednesday 10 to Saturday 13 April	07:00-19:00
Sunday 14 April	07:00-14:00

Executive lounge, faculty registration & speakers' ready room are located on 1st floor – same opening hours as registration area.

Cloakroom – Hall D

You will find the cloakroom by turning left towards Hall D from the registration area.

Wednesday 10 to Saturday 13 April	07:00-20:00
Sunday 14 April	07:00-14:00

Exhibition, EASL community hub & poster area – Hall B


Thursday 11 April	09:00*-18:30
Friday 12 and Saturday 13 April	09:00*-17:00

* Exhibitors and poster presenters have a special access as of 08:00.

What's your colour?

Follow the colour codes and pictogrammes throughout the programme to find sessions of interest to you.

Specialties



Fields



Additional icons of interest



Wi-Fi internet connection
Network: ILC2019
Password: No password necessary



DOWNLOAD THE ILC 2019 CONGRESS APP





The International Liver Congress (TM), Vienna, Austria, 10/04/2019-14/04/2019

has been granted 34 European CME credits (ECMEC®s) by the European Accreditation Council for Continuing Medical Education (EACCME®).

Daily programme at a glance

Wednesday 10 April 2019

08:00-08:30	RESEARCH THINK TANK ■ Lehar 3 Factors aggravating portal hypertension	SKILLS IN HEPATOLOGY ■ Hepatology Arena Liver tumour board	08:00-08:30
08:30-09:00	■ Lehar 1 EASL Regenerative Hepatology		08:30-09:00
09:00-09:30	■ Strauss 3 Autoimmune and cholestatic liver diseases ■ Strauss 1-2 Chronic liver failure		09:00-09:30
09:30-10:00	■ Hall C1 Liver tumours		09:30-10:00
10:00-10:30	■ Main Plenary NAFLD ■ Lehar 4 Alcoholic liver disease	SKILLS IN HEPATOLOGY ■ Hepatology Arena Vascular liver disease board	10:00-10:30
10:30-11:00	■ Hall C3 Viral Hepatitis: vaccines and prison ■ Hall C2 Hepatitis B cure ■ Lehar 2 Addressing drug user health to achieve HCV elimination		10:30-11:00
11:00-11:30			11:00-11:30
11:30-12:00		BASIC SCIENCE SEMINAR ■ Hall C3 Liver immunology and immunotherapy Liver immunology	11:30-12:00
12:00-12:30	POSTGRADUATE COURSE ■ Main Plenary End stage liver disease		12:00-12:30
12:30-13:00	Diagnosis of cirrhosis and portal hypertension: non-invasive or invasive tests?		12:30-13:00
13:00-13:30			13:00-13:30
13:30-14:00	Lunch 	Lunch 	13:30-14:00
14:00-14:30	POSTGRADUATE COURSE	BASIC SCIENCE SEMINAR ■ Hall C3 Liver immunology and immunotherapy From discovery to therapy	14:00-14:30
14:30-15:00	■ Main Plenary End stage liver disease		14:30-15:00
15:00-15:30	Bleeding and thrombosis		15:00-15:30
15:30-16:00	Coffee break 	Coffee break 	15:30-16:00
16:00-16:30	POSTGRADUATE COURSE	BASIC SCIENCE SEMINAR ■ Hall C3 Liver immunology and immunotherapy Liver inflammation and immune-oncology	16:00-16:30
16:30-17:00	■ Main Plenary End stage liver disease		16:30-17:00
17:00-17:30	Cirrhosis and comorbidities		17:00-17:30
17:30-18:00			17:30-18:00
18:00-18:30		SKILLS LEARNING CENTRE ■ SLC 1 US simulators Vascular liver disease and focal liver lesion	18:00-18:30
18:30-19:00	INDUSTRY SYMPOSIA		18:30-19:00
19:00-19:30			19:00-19:30

14:00-14:30	SYMPOSIA <ul style="list-style-type: none"> ■ Lehar 3 Liver disease in pregnancy ■ Main Plenary Albumin therapy in advanced liver disease – From plasma expander to pleiotropic agent 	PROS & CONS SESSION <ul style="list-style-type: none"> ■ Hepatology Arena Issues in the radiological evaluation of advanced hepatocellular carcinoma 	NURSES AND ALLIED HEALTH PROFESSIONALS FORUM <ul style="list-style-type: none"> ■ Lehar 2 Adding value – the role of specialist liver nurses and Allied Health Professionals 	<ul style="list-style-type: none"> ■ Hall C1 HOT TOPICS IN LIVER TRANSPLANTATION Part II Innovative strategies to increase the donor pool: Living donor liver transplant, split liver transplant, DCD 	MEET THE EXPERTS <ul style="list-style-type: none"> ■ Stolz 1 Hepatic encephalopathy ■ Stolz 2 Management of immunosuppression in AIH 	14:00-14:30
14:30-15:00	EASL-APASL SYMPOSIUM <ul style="list-style-type: none"> ■ Hall C3 Recognising and managing the lean NAFLD patient EASL-ECDC SYMPOSIUM <ul style="list-style-type: none"> ■ Lehar 4 Using real world data to inform Hepatitis B and C elimination strategies 	PROS & CONS SESSION <ul style="list-style-type: none"> ■ Hepatology Arena Patients with immunotolerant HBeAg positive infection should/should not be treated 				
15:00-15:30	FUSION HEPATOLOGY AROUND THE WORLD <ul style="list-style-type: none"> ■ Strauss 1-2 HCC – Special consideration in HBV infection EASL-ESMO SYMPOSIUM <ul style="list-style-type: none"> ■ Lehar 1 Multidisciplinary approach of Cholangiocarcinoma. From Diagnosis to treatment according to patient profile 					15:00-15:30
15:30-16:00	Coffee break 			ORAL ePOSTER 	POSTER TOUR 	15:30-16:00
16:00-16:30	PARALLEL SESSIONS <ul style="list-style-type: none"> ■ Strauss 3 Autoimmune and cholestasis II ■ Hall C3 Cirrhosis - Clinical aspects ■ Lehar 3 Liver fibrosis ■ Lehar 4 Acute and acute-on-chronic liver failure – Translational aspects ■ Strauss 1-2 Liver cancer – From Prognosis to locoregional treatments ■ Main Plenary NAFLD – Clinical Therapy ■ Hall C2 Hepatitis B – Drug development 		<ul style="list-style-type: none"> ■ Hepatology arena Critical reflection on landmark papers 2018 ■ Lehar 1 Complementarity of academia and industry in viral hepatitis elimination strategies 	<ul style="list-style-type: none"> ■ Hall C1 HOT TOPICS IN LIVER TRANSPLANTATION Part III Multidisciplinary peri-transplant management of advanced liver diseases: Critical care in transplantation 	MEET THE EXPERTS <ul style="list-style-type: none"> ■ Stolz 1 Cell therapy for liver disease ■ Stolz 2 Endoscopic versus surgical bariatric approaches as interventions for NAFLD 	16:00-16:30
16:30-17:00						
17:00-17:30						17:00-17:30
17:30-18:00						17:30-18:00
18:00-18:30						18:00-18:30
18:30-19:00	INDUSTRY SYMPOSIA		SKILLS LEARNING CENTRE <ul style="list-style-type: none"> ■ SLC 1 Diagnostic ultrasound and elastography in hepatology ■ SLC 2 Invasive diagnostics methods 			18:30-19:00
19:00-19:15						19:00-19:15
19:15-19:30			SKILLS LEARNING CENTRE <ul style="list-style-type: none"> ■ SLC 1 Diagnostic ultrasound and elastography in hepatology ■ SLC 2 Invasive diagnostics methods 			19:15-19:30
19:30-20:00						19:30-20:00



08:00-08:30	PARALLEL SESSIONS ■ Strauss 1-2 Non-invasive assessment of liver disease	SOLVE THE CASE ■ Hepatology Arena NASH	MEET THE EXPERTS ■ Stolz 1 Kidney failure after liver transplantation	08:00-08:30
08:30-09:00	■ Strauss 3 Clinical developments in rare liver disease ■ Lehar 3 Liver transplantation I		MEET THE EXPERTS ■ Stolz 2 When to use TIPS in cirrhosis	08:30-09:00
09:00-09:30	■ Hall C3 Cirrhosis – Experimental aspects	MEET THE EXPERTS ■ Stolz 2 New MRI contrast agents in the diagnosis and staging of liver tumours ■ Stolz 1 Hepatitis B: When to stop NA therapy?		09:00-09:30
09:30-09:45	■ Hall C2 Liver cancer – Systemic treatment and immunotherapy ■ Hall C1 NAFLD – Preclinical pipeline ■ Lehar 2 Gut-Liver Axis ■ Lehar 4 Alcohol related liver disease ■ Main Plenary Hepatitis C – Treatment and resistance ■ Lehar 1 Translational virology		09:30-09:45	
09:45-10:00				09:45-10:00
10:00-10:30				10:00-10:30
10:30-11:00				10:30-11:00
11:00-11:15	■ Main Plenary GENERAL SESSION III AND AWARD CEREMONY II			11:00-11:15
11:15-11:30				11:15-11:30
11:30-12:00				11:30-12:00
12:00-12:30	BASIC STATE-OF-THE-ART ■ Main Plenary Karl Wilhelm von Kupffer basic state-of-the-art: The power of ONE: Immunology in the age of single cell genomics			12:00-12:30
12:30-13:00			MEET THE EXPERTS ■ Stolz 1 Assessing patients with NASH for transplantation	12:30-13:00
13:00-13:30	INDUSTRY SYMPOSIA	ORAL ePOSTER ■ ■ ■ ■ ■	POSTER TOUR ■ ■ ■ ■ ■	13:00-13:30
13:30-14:00			MEET THE EXPERTS ■ Stolz 2 Hepatitis B: Which new drugs are in development and how do they work?	13:30-14:00
14:00-14:30	SYMPOSIUM ■ Lehar 3 Bioartificial livers, cell therapies and tissue engineering – The future of regenerative hepatology? ■ Main Plenary Patient prioritization for HCC treatment ■ Hall C3 Multidisciplinary approaches to the management of NAFLD	Y1 FUSION ■ Strauss 3 Research opportunities for young investigators in biliary diseases	THE BEST OF JHep ■ Lehar 2 2015-2019	14:00-14:30
14:30-15:00	EASL-ALEH SYMPOSIUM ■ Hall C2 DILI		YOUNG INVESTIGATORS SEMINAR ■ Lehar 4 Hepatology in 2030	MEET THE EXPERTS ■ Stolz 1 Bile duct strictures in PSC: observation or intervention? ■ Stolz 2 Gut microbiota and liver disease – where are the therapeutic opportunities?
15:00-15:30	EASL-WHO SYMPOSIUM ■ Strauss 1-2 Best practices and lessons learned from global viral hepatitis scale-up		FLASH ABSTRACT ■ Pod 1 HBV and Pregnancy	15:00-15:30
15:30-16:00			ORAL ePOSTER ■ ■ ■ ■ ■	15:30-16:00
16:00-16:30	SOLVE THE CASE ■ Hepatology Arena Cholestasis and Autoimmune		POSTER TOUR ■ ■ ■ ■ ■	16:00-16:30
16:30-17:00				16:30-17:00
17:00-17:30	SOLVE THE CASE			17:00-17:30
17:30-18:00	■ Hepatology Arena Advanced liver disease			17:30-18:00

07:30-08:00	BREAKFAST MORNING ROUNDS				07:30-08:00
	<ul style="list-style-type: none"> ■ Lehar 4 PSC: How is the surveillance? When do we need interventions (ERC), when and how to use UDC? When to consider liver transplantation? 			<ul style="list-style-type: none"> ■ Lehar 1 Extrahepatic manifestation of HCV: Response to DAA and when to use immunosuppression? 	
08:00-08:30	<ul style="list-style-type: none"> ■ Lehar 3 Cirrhosis and Portal hypertension: When TIPS, when and how Betablocker (propranolol or carvedilol?) and how to monitor? 			<ul style="list-style-type: none"> ■ Lehar 2 Hepatitis B: When to start and when to stop Nuc therapy in HBeAg negative patients? 	08:00-08:30
08:30-09:00	PARALLEL SESSIONS <ul style="list-style-type: none"> ■ Strauss 3 Liver transplantation II ■ Strauss 1-2 NAFLD – Staging and prognosis 	LIVER DISEASE AND THE COMMUNITY <ul style="list-style-type: none"> ■ Lehar 4 Part 1: EASL Policy Statements – Alcohol and food 	SOLVE THE CASE <ul style="list-style-type: none"> ■ Hepatology Arena Hepatological challenges 	MEET THE EXPERTS <ul style="list-style-type: none"> ■ Stolz 1 Portosinusoidal vascular disease: What is there behind this new name? ■ Stolz 2 Haemochromatosis 	08:30-09:00
09:00-09:30					
09:30-10:00					MEET THE EXPERTS <ul style="list-style-type: none"> ■ Stolz 2 Management of gastric varices ■ Stolz 1 Management of non response to therapy in PBC patients
10:00-10:30	Coffee break 				10:00-10:30
10:30-11:00	SYMPOSIA <ul style="list-style-type: none"> ■ Lehar 2 Preclinical models of NASH: in vitro, in vivo ■ Strauss 3 Therapy of hepatitis C after DAA failure 	LIVER DISEASE AND THE COMMUNITY <ul style="list-style-type: none"> ■ Lehar 4 Part 2: Hepatitis elimination 	PROS & CONS SESSION <ul style="list-style-type: none"> ■ Hepatology Arena PBC patients with inadequate response to UDCA: obeticholic acid or bezafibrate? 	MEET THE EXPERTS <ul style="list-style-type: none"> ■ Stolz 1 Acute liver failure ■ Stolz 2 Pharmacotherapy in NAFLD – which endpoints to use in everyday practice? 	10:30-11:00
11:00-11:30					<ul style="list-style-type: none"> ■ Lehar 3 What do you need to know about Hepatitis E
11:30-12:00	<ul style="list-style-type: none"> ■ Strauss 1-2 				11:30-12:00
12:00-12:30	ILC 2019 WRAP UP SESSION				12:00-12:30
12:30-13:00					12:30-13:00

Industry programme overview

	WEDNESDAY 10 APRIL 2019	THURSDAY 11 APRIL 2019	FRIDAY 12 APRIL 2019	SATURDAY 13 APRIL 2019					
07:30-08:00		SYMPOSIA <ul style="list-style-type: none"> ■ Strauss 1-2 Genfit: Towards a comprehensive management of patients with chronic non-viral liver diseases ■ Hall C1 Gilead: Together we can... Reducing risks in hepatitis B virus infection ■ Strauss 3 Grifols: Extending the treatment paradigm for cirrhosis: long-term albumin administration and beyond MINI-WORKSHOP <ul style="list-style-type: none"> ■ Lehar 3 Cepheid: Scaling Up Testing and Treatment for Hepatitis with Decentralised Molecular Testing 			07:30-08:00				
08:00-08:30						08:00-08:30			
12:30-13:00				SYMPOSIA <ul style="list-style-type: none"> ■ Hall C3 Gilead: Making a difference in diagnosing patients with advanced fibrosis due to NASH ■ Hall C1 MSD: Assessing Response in Advance Liver Cancer – Does Response Matter? 	12:30-13:00				
13:00-13:30					13:00-13:30				
13:30-14:00					13:30-14:00				
18:00-18:30	SYMPOSIA <ul style="list-style-type: none"> ■ Hall C3 AbbVie: Transforming the HCV Care Cascade: Making HCV Elimination a Reality ■ Strauss 3 Norgine: Preventing a domino effect in the management of hepatic encephalopathy ■ Strauss 1-2 Novo Nordisk: Understanding NASH as a metabolic disease 	SYMPOSIA <ul style="list-style-type: none"> ■ Hepatology Arena Bristol-Myers Squibb: Navigating patients through the evolving HCC treatment landscape ■ Strauss 3 Intercept: Advances in PBC Management: Looking Beyond Biochemical Markers 	MINI-WORKSHOPS <ul style="list-style-type: none"> ■ Lehar 3 Alexion: My patient care vs restricted access to medicines ■ Lehar 4 Sequana Medical: Managing Ascites, improving Quality of Life 	SYMPOSIA <ul style="list-style-type: none"> ■ Main Plenary Gilead: Together we can... Achieving HCV elimination through simplification ■ Hepatology Arena Intercept: NASH: What does the evidence tell us? ■ Strauss 3 Shionogi: Procedural risk of bleeding – does the management of TCP in CLD patients make a difference? A debate 	MINI-WORKSHOP <ul style="list-style-type: none"> ■ Lehar 3 Perspectum Diagnostics: Introducing quantitative MRCP: Improving the clinical landscape for biliary disease 	18:00-18:30			
18:30-19:00									18:30-19:00
19:00-19:30									
19:30-20:00					19:30-20:00				

Ground floor overview



Hall B – Exhibition, EASL community hub & poster area




Exhibitors' list

Company	Booth Space	Company	Booth Space
AASLD: American Association for the Study of Liver Diseases	420	EFSUMB: European Federation of Societies for Ultrasound	349
AbbVie	140	Eiger BioPharmaceuticals, Inc.	109
Albutec GmbH	Biotech Village	ELPA: European Liver Patients' Association	401, 410
ALEH: Latin American Association for the Study of the Liver	350	Enanta Pharmaceuticals	251
Alexion Pharma GmbH	220	Endra Life Sciences	114
Allergan	250	FIANOSTICS GmbH	455
Alynlam Pharmaceuticals	346	Fujirebio Europe NV	336
APASL: Asian Pacific Association for the Study of the Liver	432	Genedrive Diagnostics Ltd.	433
APHC: PHC 2020	434	Genfit	240
Apollo Endosurgery UK Ltd	302	Gilead Sciences Europe Ltd	360, 370, 380
Barcelona Liver Bioservices – BLB	Biotech Village 1	GMP Orphan Deutschland GmbH	435
BioPredictive	303	Gore & Associates	320
Biotech AG	143	Grifols	332
Bristol-Myers Squibb	Delegates Lounge	Gubra ApS	431
Cepheid	300	Helena Biosciences	260
CymaBay Therapeutics	253	Hep C Action Aotearoa	344
Diafir	Biotech Village 2	High Point Clinical Trials Center	443
Dr. Falk Pharma GmbH	200	Humedics	155
Echosens	330	ICE-HBV: International Coalition to Eliminate HBV	351

Company	Booth Space
INHSU: International Network on Hepatitis in Substance Users	343
Intercept	160, 352
Ipsen	400
Liver Systems Medicine (LiSyM) Network	Biotech Village
Liverpool Drug Interactions	340
MSD	230
MYR Pharma	450
Norgine	150
Novartis Pharma AG	210
Novo Nordisk A/S	102
OraSure Technologies	163
Perspectum Diagnostics	130
Philips Healthcare	115
PhoenixBio	430
Promethera Biosciences	Biotech Village 6
ProSciento	451
Research Diets, Inc.	156
Resoundant Inc.	270
Sanyal Biotechnology LLC	Biotech Village 3
Sequana Medical NV	Biotech Village 4
Shionogi Limited	338
Siemens Healthcare GmbH	161

Company	Booth Space
SuperSonic Imagine	110
TASL: Taiwan Association for the Study of the Liver	339
The Cochrane Hepato-Biliary Group	337
United European Gastroenterology (UEG)	345
VIDC: Vancouver Infectious Diseases Centre	334
Virology Education	348
VLVbio	Biotech Village 5
WGO: World Gastroenterology Organisation	342
WHA: World Hepatitis Alliance	153
Wisepress	440
Zero Gravity Skin	442

Hall B – Poster area overview



The background features abstract, flowing shapes in shades of light blue and white, creating a sense of movement and depth. The shapes are smooth and organic, resembling liquid or soft fabric. The text is overlaid on the upper portion of this background.

SEE YOU AT **ILC 2020** LONDON

www.easl.eu